Johnson & Johnson
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JNJ research report →
Range $260 – $320
Price Chart
About the company
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
- CEO
- Joaquin Duato
- IPO
- 1962
- Employees
- 141,700
- HQ
- New Brunswick, NJ, US
Get TickerSpark's AI analysis on JNJ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $651.11B
- P/E
- 41.34
- Fwd P/E
- 24.34
- PEG
- -1.13
- P/S
- 6.61
- P/B
- 8.19
- EV/EBITDA
- 25.52
- Div Yield
- 1.94%
- Gross Margin
- 67.56%
- Op Margin
- 25.17%
- Net Margin
- 16.20%
- ROE
- 19.55%
- ROIC
- 15.04%
Latest fiscal year · YoY change
- Revenue
- $94.19B+6.0%
- Gross Profit
- $63.94B+4.2%
- Op Income
- $25.60B
- Net Income
- $26.80B+90.6%
- EPS
- $11.03+88.9%
- OCF Growth
- +1.1%
- FCF Growth
- -0.7%
- 52W High
- $290.25
- 52W Low
- $199.91
- 50D MA
- $267.33
- 200D MA
- $250.66
- Beta
- 0.23
- RSI (14)
- 48
- Avg Volume
- 7.20M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Johnson & Johnson said Q3 growth accelerated, beat expectations, and management raised 2026 guidance while pointing to a path toward double-digit growth by the end of the decade.· October 13, 2026
- Worldwide sales were $25.4 billion, up 6% operationally, with U.S. growth of 9.1% and outside-U.S. growth of 1.8%.
- Adjusted diluted EPS was $2.59, down 7.5% year over year, while reported diluted EPS was $0.09 versus $2.12 last year due to talc, Firefly Bio, and Cell BioMedicines-related charges.
- Innovative Medicine was the main driver, with sales of $16.8 billion up 7.9%; Tremfya rose 68.2%, CAPLYTA rose 66.1%, and oncology grew about 17%.
- MedTech grew 2.5%, but management said performance fell short of expectations, with pressure in cardiovascular outside the U.S., surgery outside the U.S., and Abiomed.
- Full-year 2026 operational sales guidance was raised to 6.7% to 7.1%, and adjusted operational EPS guidance was set at $10.95 to $11.05.
Johnson & Johnson reported third-quarter 2026 worldwide sales of $25.4 billion, up 6% operationally. U.S. sales grew 9.1% and international sales grew 1.8% operationally. Reported net earnings were $210 million and diluted EPS was $0.09 versus $2.12 a year ago; adjusted net earnings were $6.3 billion and adjusted diluted EPS was $2.59, down 6.8% and 7.5%, respectively. Innovative Medicine sales were $16.8 billion, up 7.9%, and MedTech sales were $8.6 billion, up 2.5%. The company raised full-year 2026 operational sales guidance to 6.7% to 7.1% and adjusted operational EPS guidance to $10.95 to $11.05, with reported adjusted EPS guidance of $11.05 to $11.15. Management also said it expects full-year free cash flow of $21 billion and approximately 60 basis points of operating margin decline for 2026. The company cited about $7 billion of charges in the quarter tied to the proposed talc litigation resolution and expenses related to Firefly Bio and Cell BioMedicines.
Joaquin Duato framed the quarter as evidence that Johnson & Johnson is entering a period of accelerated growth, saying the company is on track to exceed $100 billion in annual revenue for the first time. He emphasized breadth across innovation in oncology, immunology, neuroscience, cardiovascular and surgery, and said the company has a clear path to double-digit growth by the end of the decade. His tone was confident, repeatedly pointing to launch momentum, pipeline depth, and the idea that 2027 will be an even better year.
Joe Wolk said the quarter was driven by strength in Innovative Medicine, which more than offset MedTech headwinds, and that the company is raising guidance based on year-to-date performance and fourth-quarter expectations. He highlighted approximately $17 billion of cash and marketable securities, approximately $45 billion of debt, net debt of approximately $28 billion, and more than $6 billion of free cash flow in Q3. He said the Firefly Bio and Cell BioMedicines transactions had a combined $0.64 per-share impact this year and will have a $1.36 per-share dilutive impact next year, while also noting the company expects margins to improve on a base business basis despite deal-related pressure.
Analysts focused on whether Johnson & Johnson’s double-digit growth ambition depends on M&A and whether the MedTech slowdown means the company needs more acquisitions. Wolk said the double-digit growth plan is based on internal strategic investments, not inorganic additions, while still leaving room for complementary deals if they make sense. On MedTech, management said the issue is concentrated in cardiovascular and surgery outside the U.S. plus Abiomed, and that they are taking corrective action rather than viewing the problems as structural. Questions also centered on ICOTYDE, INLEXZO, and myeloma CAR-T; management said ICOTYDE is off to a strong start with over 20,000 patients initiated and that INLEXZO reached nearly $200 million in year-to-date sales, while CARVYKTI is already being used earlier in treatment with education focused on patient selection and access.
The bull case from this call is that Johnson & Johnson has multiple growth engines working at once: strong Innovative Medicine momentum, a growing set of billion-dollar brands, and new launches that management believes can expand further. Management also sounded confident that MedTech’s weaker quarter was temporary and that launches like OTTAVA, VARIPULSE Pro, and ongoing evidence generation could re-accelerate growth. The raised 2026 outlook and repeated references to double-digit growth by decade-end reinforce that leadership sees the business as underpinned by durable expansion.
The main bear case is that reported earnings were heavily distorted by about $7 billion of charges, including the talc litigation resolution and acquisition-related expenses, which pulled GAAP EPS down sharply. MedTech missed expectations, with management flagging issues in cardiovascular outside the U.S., surgery outside the U.S., and Abiomed, and saying it must take action to improve performance. There are also competitive and execution risks in biosimilars, competitive PFA pressures, and uncertainty around future pipeline readouts and the 2027 separation of DePuy Synthes.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 2.41B
- Float Shares
- 2.40B
of shares held by institutions
4,831 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for JNJ, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Thomas KeanHouse · NJ07 | Sell | Oct 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Thomas KeanHouse · NJ07 | Sell | Sep 30, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 25, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Lloyd DoggettHouse · TX37 | Buy | Sep 8, 26 | Filing → |
| Thomas KeanHouse · NJ07 | Sell | Aug 27, 26 | Filing → |
| John BoozmanSenate · AR | Sell | Aug 20, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 7, 26 | Filing → |
| Rich McCormickHouse · GA06 | Sell | Jul 30, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 2, 26 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Oct 29, 24 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 30, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 240.35M | ▲ 3.73M |
| Blackrock, Inc. | 209.72M | ▼ 2.38M |
| Vanguard Capital Management LLC | 157.76M | ▲ 530.87K |
| State Street Corp | 133.97M | ▲ 195.31K |
| Vanguard Portfolio Management LLC | 65.65M | ▲ 1.28M |
| Geode Capital Management, LLC | 65.50M | ▲ 6.41M |
| Jpmorgan Chase & Co | 61.75M | ▲ 3.45M |
| Morgan Stanley | 44.68M | ▼ 125.95K |
| Norges Bank | 31.83M | ▲ 31.83M |
| State Farm Mutual Automobile Insurance Co | 31.59M | 0 |
| Northern Trust Corp | 28.20M | ▼ 594.73K |
| Capital World Investors | 26.32M | ▲ 11.10M |
Held by 2,561 ETFs
Biggest fund positions in JNJ by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Forminard Elizabeth | other | 13,072 |
| Nov 12, 26 | Forminard Elizabeth | sell | 13,072 |
| Nov 12, 26 | Forminard Elizabeth | other | 13,072 |
| Sep 8, 26 | Pinto Daniel E | other | 113.098 |
| Sep 8, 26 | Woods Eugene A. | other | 135.717 |
| Sep 8, 26 | HEWSON MARILLYN A | other | 180.956 |
| Sep 2, 26 | Schmid Timothy | other | 22,527 |
| Sep 2, 26 | Schmid Timothy | other | 11,070 |
| Sep 2, 26 | Schmid Timothy | sell | 22,527 |
| Sep 2, 26 | Schmid Timothy | other | 11,070 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our JNJ coverage
Recent articles, reports, and earnings notes.

Johnson & Johnson (JNJ): Growth Broadens Beyond STELARA
Johnson & Johnson is a Buy as newer medicines and MedTech growth offset STELARA’s decline. The stock looks fairly valued to slightly attractive with strong cash generation and a broad pipeline.

Top Healthcare Dividend Stocks: Our 5 Picks for November 2026
Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.

Johnson & Johnson (JNJ) drops 5% after mixed Q3
Johnson & Johnson (JNJ) drops after a mixed Q3 earnings report. The company beat adjusted EPS and revenue estimates and raised guidance, but reported profit fell and MedTech sales faced Middle East-related pressure, prompting investors to reassess the stock’s premium valuation.
Want a deeper read on JNJ?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
These 4 Conservative Dow Jones Industrials Dividend Stocks Are Built for Sell-Offs
247wallst.com · Nov 20
How Retirees Can Turn $750,000 Into Passive Income With These 5 Dividend Stocks
247wallst.com · Nov 20
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
zacks.com · Nov 20
Money Market Funds vs. Dividend Stocks: Where Retirees Should Keep Their Cash
247wallst.com · Nov 20
Want Reliable Dividend Passive Income? These 5 Stocks Raise Their Payouts Year After Year
247wallst.com · Nov 20
Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
prnewswire.com · Nov 20
Johnson & Johnson $JNJ Shares Sold by Berger Financial Group Inc
defenseworld.net · Nov 20
Stock Screening Made Simple: A Closer Look
zacks.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.